Medical Device News Magazine

Violet Defense Offers Affordable Disinfection as a Service to Respond to COVID-19 Surges

UV disinfection products safely kill COVID-19, flu, and Norovirus to protect people, industries, and the environment

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Violet Defense notes as the Omicron coronavirus variant sweeps the country and COVID-19 cases surge, many businesses are trying to ride it out with standard or even diminished precautions.

Violet Defense, a UV disinfection technology company, provides a better, sustainable, and long-term solution that is now available as a service.

Violet Defense is the developer of patented ultraviolet (UV) light technology proven in laboratory tests to kill bacteria and viruses, including coronavirus, norovirus, E. coli, C. diff, C. auris, Salmonella and MRSA. Its pulsed Xenon solution can be permanently installed or used in portable units.

Public-serving organizations are trying to remain open during the latest coronavirus resurgence, using standard chemical disinfection methods that have been insufficient and put workers at risk. Meanwhile, employees and customers are less often using precautions like social distancing and masks. That translates to increased risk of infection.

“The rapid spread of the latest COVID-19 variant has shown clearly that we don’t have the proper protections in place,” said Violet Defense CEO Terrance Berland. “Superior disinfection practices are not a luxury to aspire to anymore, they are a necessity, and UV disinfection is a proven way to keep people safe.”

Schools, hospitals, and all types of businesses are struggling to stay open as large numbers of employees become ill and quarantine. Even after the coronavirus pandemic subsides, illnesses like influenza will pose the same problem. That reminds us that vaccination, rapid testing and contact tracing alone cannot keep the public safe – frequent, thorough and effective disinfection is also vital.

With that in mind, Violet Defense is developing a new business model, Disinfection as a Service, where businesses can install its UV disinfection products via a lease-style arrangement, making it an operating expense instead of a capital purchase. The small Violet Defense unit would cost little more than $1 per disinfection cycle.

“We have a responsibility to protect our children, first responders, teachers, business owners – everyone. In that sense, disinfection is essentially a public service,” Berland said. “With Violet Defense’s new program, it’s an easy choice to get the best disinfection possible – at little more than $1 per disinfection cycle, how can you afford not to?”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”